BeOne Medicines (SHA:68823) returned to a net profit of $94.3 million in the second quarter from a loss of $120.9 million in the year-ago period, according to a Thursday filing with the Shanghai bourse.
The pharmaceutical company, formerly BeiGene, recorded earnings per share of $0.06 compared with a loss per share of $0.09 in the prior-year period.
Revenue increased 42% to $1.3 million from $929,166 in the year-ago period.
Shares fell 3% in Shanghai and 1% in Hong Kong during late morning trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.